107 related articles for article (PubMed ID: 20375985)
1. Visfatin is upregulated in type-2 diabetic rats and targets renal cells.
Kang YS; Song HK; Lee MH; Ko GJ; Han JY; Han SY; Han KH; Kim HK; Cha DR
Kidney Int; 2010 Jul; 78(2):170-81. PubMed ID: 20375985
[TBL] [Abstract][Full Text] [Related]
2. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy.
Song HK; Lee MH; Kim BK; Park YG; Ko GJ; Kang YS; Han JY; Han SY; Han KH; Kim HK; Cha DR
Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1485-94. PubMed ID: 18768589
[TBL] [Abstract][Full Text] [Related]
3. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
[TBL] [Abstract][Full Text] [Related]
4. Visfatin, a novel adipokine, stimulates glucose uptake through the Ca2 +-dependent AMPK-p38 MAPK pathway in C2C12 skeletal muscle cells.
Lee JO; Kim N; Lee HJ; Lee YW; Kim JK; Kim HI; Lee SK; Kim SJ; Park SH; Kim HS
J Mol Endocrinol; 2015 Jun; 54(3):251-62. PubMed ID: 26019302
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients.
Kang YS; Song HK; Lee MH; Ko GJ; Cha DR
Diabetes Res Clin Pract; 2010 Aug; 89(2):141-9. PubMed ID: 20409603
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like effects of visfatin on human osteoblasts.
Xie H; Tang SY; Luo XH; Huang J; Cui RR; Yuan LQ; Zhou HD; Wu XP; Liao EY
Calcif Tissue Int; 2007 Mar; 80(3):201-10. PubMed ID: 17340225
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
[TBL] [Abstract][Full Text] [Related]
8. Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice.
Kang YS; Lee MH; Song HK; Kim JE; Ghee JY; Cha JJ; Lee JE; Kim HW; Han JY; Cha DR
Kidney Blood Press Res; 2016; 41(3):311-24. PubMed ID: 27221663
[TBL] [Abstract][Full Text] [Related]
9. Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells.
Huang Q; Guo Y; Zeng H; Xie W; Yan H; Ding H
Endocr Res; 2011; 36(3):93-100. PubMed ID: 21314328
[TBL] [Abstract][Full Text] [Related]
10. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions.
Adeghate E
Curr Med Chem; 2008; 15(18):1851-62. PubMed ID: 18691043
[TBL] [Abstract][Full Text] [Related]
11. Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats.
Okada M; Takemura T; Yanagida H; Yoshioka K
Kidney Int; 2002 Jan; 61(1):113-24. PubMed ID: 11786091
[TBL] [Abstract][Full Text] [Related]
12. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats.
Cha JJ; Kang YS; Hyun YY; Han SY; Jee YH; Han KH; Han JY; Cha DR
Life Sci; 2013 Jun; 92(23):1118-24. PubMed ID: 23643633
[TBL] [Abstract][Full Text] [Related]
13. Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats.
Wang P; Bai C; Xu QY; Xu TY; Su DF; Sassard J; Miao CY
Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):894-9. PubMed ID: 20456420
[TBL] [Abstract][Full Text] [Related]
14. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide.
Wang P; Xu TY; Guan YF; Su DF; Fan GR; Miao CY
Cardiovasc Res; 2009 Feb; 81(2):370-80. PubMed ID: 18952695
[TBL] [Abstract][Full Text] [Related]
15. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?
Bełtowski J
Med Sci Monit; 2006 Jun; 12(6):RA112-9. PubMed ID: 16733497
[TBL] [Abstract][Full Text] [Related]
16. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids.
Chang YC; Chang TJ; Lee WJ; Chuang LM
Metabolism; 2010 Jan; 59(1):93-9. PubMed ID: 19765775
[TBL] [Abstract][Full Text] [Related]
17. Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats.
Lv Q; Wang Y; Wang W; Wang L; Zhou X
Endocr Res; 2009; 34(4):130-41. PubMed ID: 19878073
[TBL] [Abstract][Full Text] [Related]
18. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
de Boer JF; Bahr MJ; Böker KH; Manns MP; Tietge UJ
Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G196-201. PubMed ID: 19074645
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
Axelsson J; Witasp A; Carrero JJ; Qureshi AR; Suliman ME; Heimbürger O; Bárány P; Lindholm B; Alvestrand A; Schalling M; Nordfors L; Stenvinkel P
Am J Kidney Dis; 2007 Feb; 49(2):237-44. PubMed ID: 17261426
[TBL] [Abstract][Full Text] [Related]
20. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.
Chen MP; Chung FM; Chang DM; Tsai JC; Huang HF; Shin SJ; Lee YJ
J Clin Endocrinol Metab; 2006 Jan; 91(1):295-9. PubMed ID: 16234302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
